The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

Trial Details
Trial status:
Recruitment start date:
Cancer Research UK
Chief Investigator:
Prof. Peter Hoskin
Recruitment target:
EudraCT number:
Contact details:
Lay summary:
A randomised phase III trial of single fraction radiotherapy compared to multifraction radiotherapy in patients with metastatic spinal cord compression (SCC).
Design: SCORAD III was a multicentre, randomised phase III trial, stratified according to radiotherapy centre, ambulatory status, type of primary tumour and extent of disease (presence or absence of nonskeletal metastases).

Arm 1: Multiple fraction radiotherapy  20Gy/5f
Arm 2: Single fraction radiotherapy     8Gy/1f

Key inclusion/exclusion criteria:
  • Decision to treat made ≤48 hours before SCC treatment.  
  • Single compression site or multiple sites treated in one radiation field
  • Malignant disease confirmed histologically or cytologically or a PSA >100 ng/ml at any point before randomisation (if biopsy done or planned but results not yet available patients may enter)
  • Life expectancy >8 weeks

  • Surgery or chemotherapy more appropriate
  • Multiple myeloma, lymphoma, leukaemia or glioma
  • Prophylactic treatment with no radiological spinal cord or cauda equina compression
  • Compression site has been treated previously with radiotherapy

Duration of recruitment: 6 Years (closed to recruitment 30 April 2016). 611 patients were randomised from 47 sites.
SCC is a common complication of metastatic cancer.  The main treatment is radiotherapy, to preserve or recover neurological function and prevent further progression of symptoms. There is currently no standard fractionation schedule. The aim is to show that ambulatory status using 8Gy/1f is no worse than with 20Gy/5f for patients with SCC. 
The primary endpoint is ambulatory status at 8 wks from treatment day 1, compared to randomisation.

Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
NameVersionCurrent versRelease dateDownload
current SCORAD III protocol4 Current 03/03/2013
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us